Aetion recognized by Goldman Sachs for entrepreneurship

NEW YORK, Oct. 17, 2018 /PRNewswire/ — Aetion, the software platform company with the real-world analytics and evidence needed for biopharma and payers to engage in value-based care, today announced that Goldman Sachs is recognizing CEO Carolyn Magill as one of the 100 Most Intriguing Entrepreneurs of 2018 at its annual Builders + Innovators Summit.

Goldman Sachs selected Magill from entrepreneurs across industries for its two-day event, which begins today in Santa Barbara, California.

Aetion’s software platform, the Aetion Evidence Platform®, was created to address a widely recognized need: automation of causal analytics in real-world data, at the highest level of scientific rigor. This allows users to unlock — from existing clinical data — essential insights about the effectiveness, safety, and value of medications and treatments.

“One of the biggest needs in health care is figuring out a treatment’s true impact. Real-world data and analytics are critical tools to assess this,” said Carolyn Magill, chief executive officer of Aetion. “We’re proud to work with leading payers and seven of the top 15 biopharma firms to determine what treatments work best, for whom, and when. Together, we can drive better health care decisions and outcomes — using the data that’s generated through health care’s everyday transactions.”

“A dynamic economy depends on dynamic entrepreneurs who disrupt industries and occasionally give birth to entirely new sectors,” said David M. Solomon, chief executive officer of Goldman Sachs. “The purpose of Builders + Innovators is to support emerging leaders in their quests to innovate faster in order to grow their ideas. We are pleased to recognize Carolyn Magill as one of the most intriguing entrepreneurs of 2018.”

In addition to the Goldman Sachs Builders + Innovators Summit, Aetion will present at a range of industry-leading conferences, including:

To meet with an Aetion representative at any of the conferences listed above, contact

About Aetion

Based in New York City, Aetion is a leading health care technology company that delivers the real-world analytics and evidence needed for pharmaceutical developers and purchasers to thrive in value-based care. With its patented rapid-cycle analytics technology, the Aetion Evidence Platform uses the everyday clinical and financial interactions of the health care system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and a big data pioneer, Aetion enables biopharma companies and payers to collaborate in real-time to develop therapeutic insights so patients get the most clinically effective — and cost-effective — care. Learn more at

About the 2018 Builders + Innovators Summit

For nearly 150 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.